TL;DR:
- The fight is already on: House and Senate Republicans are urging Trump to abandon rescheduling, using public health, youth-safety and cartel rhetoric while targeting the 280E tax break as a key issue.
- Authority and leverage are part of the story: Opponents argue Trump can’t “just do it” by executive order, but reversing an administrative move in Congress would be difficult once it’s underway.
- Timing hints at choreography: Industry reporting suggests rescheduling may be tied to internal administration sequencing, including movement on the “drug czar” nomination, underscoring that this is about control as much as policy.
As reports mount that President Donald Trump may soon move cannabis from Schedule I to Schedule III under the Controlled Substances Act, the political battle in Washington is already underway. Not over legalization. Not over justice. But over who gets to define cannabis and who benefits from that definition.
Republican lawmakers are urging Trump to abandon the reported plan, warning that rescheduling would “send the wrong message to America’s children,” fuel drug cartels and worsen public safety. At the same time, industry observers and policy reporters are tracking a quieter but equally consequential set of moves inside the federal government that suggest rescheduling, if it happens, will be tightly managed and carefully framed.
The result is a familiar dynamic in U.S. cannabis policy: progress acknowledged in principle, while control remains the central prize.
A last-ditch push to stop rescheduling
In reporting by Marijuana Moment, Tom Angell detailed how groups of Republican lawmakers in both the House and Senate sent letters to Trump urging him not to proceed with rescheduling, framing the move as dangerous, unnecessary and politically misguided. The House letter, led by Reps. Pete Sessions and Andy Harris, described cannabis as a “harmful drug” that would worsen addiction and endanger public safety if reclassified. The Senate letter echoed those concerns, arguing that rescheduling would undermine Trump’s broader political and economic agenda.
The lawmakers also focused heavily on taxation, warning that rescheduling would allow cannabis businesses to escape the federal 280E tax penalty and claim standard business deductions. In their telling, that tax relief would benefit “addiction-for-profit dispensaries” and, more controversially, allegedly Chinese-linked illicit grow operations operating under state licenses.
The language is sweeping, alarmist and familiar. Cannabis, they argue, has no accepted medical value. Rescheduling, they claim, would normalize drug use, mislead young people and worsen an already fragile public health landscape.
Yet the letters also reveal something else: a clear recognition that Schedule III would not legalize cannabis, only reshape the federal government’s posture toward it.
Can Trump do this on his own?
A separate Marijuana Moment report by Kyle Jaeger focused on a different argument raised by opponents: whether Trump even has the authority to reschedule cannabis unilaterally. Rep. Andy Harris, speaking during a webinar, said the president is “technically” unable to reschedule marijuana via executive order alone, though he acknowledged that reversing an administrative move through Congress would be difficult.
Under the Controlled Substances Act, authority to reschedule drugs formally rests with the attorney general and is typically delegated to the Drug Enforcement Administration. An executive order could direct agencies to act, but it would still rely on administrative follow-through and would remain vulnerable to political pressure and legal challenges.
In other words, even critics of rescheduling acknowledge that once the machinery starts moving, stopping it may be harder than launching it.
The timing question no one can ignore
Where Cannabis Business Times adds critical context is in its examination of timing. In a report that has circulated widely inside the industry, the outlet connected Trump’s recent public confirmation that he is considering rescheduling with the Senate’s move to advance the confirmation of Sara Carter Bailey as director of the White House Office of National Drug Control Policy.
The ONDCP director, often referred to as the nation’s “drug czar,” plays a central role in shaping federal drug policy. While Bailey avoided taking clear positions on rescheduling during her confirmation process, past comments suggest openness to medical cannabis. Her confirmation would place a key institutional player in position at the exact moment rescheduling is being considered.
That sequencing matters. It suggests that rescheduling, if announced, is less a spontaneous political gesture and more the final step in a carefully staged administrative process.
What rescheduling does (and doesn’t) change
If cannabis moves to Schedule III, it would no longer sit alongside heroin and LSD as a substance deemed to have no medical value. That alone would mark a historic shift in federal language. It could ease certain research barriers and allow state-legal cannabis businesses to deduct ordinary expenses under federal tax law.
But it would not legalize cannabis federally. It would not decriminalize possession. It would not mandate banking access, end interstate barriers or address the status of people still incarcerated for cannabis-related offenses.
What it would do is redefine cannabis in regulatory terms and shift leverage toward federal agencies at a moment when the industry, patients and consumers are still operating under a patchwork of state laws.
That is why the fight unfolding now is not simply about whether cannabis is rescheduled. It is about who controls the narrative that follows.
A familiar pattern
Opponents warn that rescheduling sends the wrong message. Supporters argue it does not go far enough. Industry voices parse tax implications and research access. Meanwhile, the lived reality for consumers and communities remains largely unchanged.
This tension has defined U.S. cannabis policy for decades. Progress arrives in increments, framed as historic, while prohibition’s underlying structure adapts rather than disappears.
If cannabis is rescheduled in the coming days, it will matter. But the louder signal may be what comes next: a renewed struggle over whether cannabis is treated primarily as medicine, as risk, as commodity or as culture.
Before cannabis is rescheduled, Washington is already fighting over who controls it. The outcome of that fight will shape far more than a line in the federal drug code.
